Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
PASC Post Acute Sequelae of COVID-19
Interventions
DRUG

A.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)

Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and an additional 30-minute static scan at 4 hours post-injection. Blood samples (up to 42 mL total) are collected during dynamic imaging.

DRUG

A.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)

Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.

DRUG

B.1 - [¹⁸F]F-AraG PET/CT (90-min dynamic + 4-h static)

Participants receive an intravenous injection of 5 mCi (±20%) of \[¹⁸F\]F-AraG followed by a 90-minute total-body PET/CT scan and a second 30-minute scan at 4 hours. Blood samples (up to 42 mL total) are collected during dynamic imaging.

DRUG

B.2 - [¹⁸F]F-AraG PET/CT (60-min dynamic only)

Participants receive 5 mCi (±20%) of \[¹⁸F\]F-AraG intravenously followed by a 60-minute total-body PET/CT scan. Blood samples (up to 42 mL total) are collected during dynamic imaging.

Trial Locations (2)

94110

University of California San Francisco, San Francisco

95816

UC Davis EXPLORER Molecular Imaging Center, Sacramento

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

University of California, San Francisco

OTHER

lead

University of California, Davis

OTHER

NCT07076862 - Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) | Biotech Hunter | Biotech Hunter